Abstract
The 5-HT1A receptor has been extensively studied over the last two decades. There is a plethora of information describing its anatomical, physiological and biochemical roles in the brain. In addition, the development of selective pharmacological tools coupled with our understanding of psychiatric pathology has lead to multiple hypotheses for the therapeutic utility of 5-HT1A agents and in particular 5-HT1A receptor antagonists. Over the last decade it has been suggested that 5-HT1A receptor antagonists may have therapeutic utility in such diseases as depression, anxiety, drug and nicotine withdrawal as well as schizophrenia. However, a very compelling rationale has been developed for the therapeutic potential of 5-HT1A receptor antagonists in Alzheimers disease and potentially other diseases with associated cognitive dysfunction. Receptor blockade by a 5-HT1A receptor antagonist appears to enhance activation and signaling through heterosynaptic neuronal circuits known to be involved in cognitive p rocesses and, as such, represents a novel therapeutic approach to the treatment of cognitive deficits associated with Alzheimers disease and potentially other disorders with underlying cognitive dysfunction.
Keywords: 5-HT1A Receptor Antagonists, Alzheimers Disease
Current Pharmaceutical Design
Title: The Potential Utility of 5-HT1A Receptor Antagonists in the Treatment of Cognitive Dysfunction Associated with Alzheimers Disease
Volume: 8 Issue: 2
Author(s): L. E. Schechter, L. A. Dawson and J. A. Harder
Affiliation:
Keywords: 5-HT1A Receptor Antagonists, Alzheimers Disease
Abstract: The 5-HT1A receptor has been extensively studied over the last two decades. There is a plethora of information describing its anatomical, physiological and biochemical roles in the brain. In addition, the development of selective pharmacological tools coupled with our understanding of psychiatric pathology has lead to multiple hypotheses for the therapeutic utility of 5-HT1A agents and in particular 5-HT1A receptor antagonists. Over the last decade it has been suggested that 5-HT1A receptor antagonists may have therapeutic utility in such diseases as depression, anxiety, drug and nicotine withdrawal as well as schizophrenia. However, a very compelling rationale has been developed for the therapeutic potential of 5-HT1A receptor antagonists in Alzheimers disease and potentially other diseases with associated cognitive dysfunction. Receptor blockade by a 5-HT1A receptor antagonist appears to enhance activation and signaling through heterosynaptic neuronal circuits known to be involved in cognitive p rocesses and, as such, represents a novel therapeutic approach to the treatment of cognitive deficits associated with Alzheimers disease and potentially other disorders with underlying cognitive dysfunction.
Export Options
About this article
Cite this article as:
Schechter E. L., Dawson A. L. and Harder A. J., The Potential Utility of 5-HT1A Receptor Antagonists in the Treatment of Cognitive Dysfunction Associated with Alzheimers Disease, Current Pharmaceutical Design 2002; 8 (2) . https://dx.doi.org/10.2174/1381612023396483
DOI https://dx.doi.org/10.2174/1381612023396483 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurorescue Activity, APP Regulation and Amyloid-β Peptide Reduction by Novel Multi-Functional Brain Permeable Iron- Chelating- Antioxidants,M-30 and Green Tea Polyphenol, EGCG
Current Alzheimer Research RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry Something Old, Something New and Something Used in Alzheimer's; the Idea of Pore, Ethanol and the Use of Oocytes to Understand the Disease
Current Chemical Biology Monoamine Receptors and Signal Transduction Mechanisms in Suicide
Current Psychiatry Reviews Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Macrophages: Promising Targets for the Treatment of Atherosclerosis
Current Vascular Pharmacology Carbon Monoxide and Iron Modulate Plasmatic Coagulation in Alzheimer’s disease
Current Neurovascular Research 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies
Current Alzheimer Research Concluding Notes of Special Issue “α-7 Nicotinic Receptor (α7-nAChR): One Target Different Diseases”
Current Drug Targets Opioid Receptors and their Ligands
Current Topics in Medicinal Chemistry PM6, PM7 and RM1 Quantum Chemistry Modeling of MEH-PPV and PEDOT Polymers
Current Physical Chemistry Role of Copper in Angiogenesis and Its Medicinal Implications
Current Medicinal Chemistry Long Non-coding RNA HOTAIR Promotes Parkinson's Disease Induced by MPTP Through up-regulating the Expression of LRRK2
Current Neurovascular Research Recent Developments of the PET Imaging Agents for Metabotropic Glutamate Receptor Subtype 5
Current Topics in Medicinal Chemistry Encapsulation in Cell Therapy: Methodologies, Materials, and Clinical Applications
Current Pharmaceutical Biotechnology Combining Stress and Dopamine Based Models of Addiction: Towards a Psycho-Neuro-Endocrinological Theory of Addiction
Current Drug Abuse Reviews In Vivo Models of Childhood Leukemia for Preclinical Drug Testing
Current Drug Targets Polyunsaturated Fatty Acids in Emerging Psychosis
Current Pharmaceutical Design Significant Overlapping Modules and Biological Processes Between Stroke and Coronary Heart Disease
CNS & Neurological Disorders - Drug Targets